Johnson & Johnson (NYSE:JNJ) Profit Outshines Wall Street Estimates – JNJ, SNY, MYL, CNMD

Johnson & Johnson (NYSE:JNJ) announced on Tuesday that profit in fiscal Q1 plunged from previous year. However results surpassed forecasts on strong pharmaceutical sales.

Healthcare giant announced net earnings moved down to $3.5 billion or $1.22 a share from previous year’s $3.91 billion or $1.41 a share. But, the company was able to back its full year profit estimates.

Most recent period results comprised after-tax special items of almost $600 million, linked with setting lawsuits and its purchase of Synthes.

Quarterly adjusted net earnings $1.44 a share, while it was $1.37 a share a year ago. Thomson Reuters 18 analysts’ survey on average forecasted EPS of $1.40. Analysts’ forecasts usually exclude special items.

Sales moved up 8.5% to $17.51 billion from $16.14 billion, surpassing median forecasts of $17.44 billion.

Shifting reader’s focus to broader market, let us consider market performance of other stocks that significantly affect same sector. Sanofi SA (ADR) (NYSE:SNY) rose +1.02% to settle at $54.37, Mylan Inc. (NASDAQ:MYL) moved up +0.71% to end at $28.30 while CONMED Corporation (NASDAQ:CNMD) jumped +1.39% to finish at $32.82on Tuesday.

Johnson & Johnson (NYSE:JNJ) last session’s volume of 12.62 million shares was higher than its average volume of 9.82 million shares. The stock after opening at $82.33 hit high price of $83.54 and then closed at $83.44 by scoring +2.12%.

JNJ generated revenue of $67.22 billion in the previous twelve months and earned $10.85 billion. The Company showed a positive 15.64% in the net profit margin as well as in its operating margin which remained at 20.49%. Company’s annual sales growth for the past five years was 1.93%.

The JNJ’s past twelve months’ price to sales ratio was 3.47 and price to cash ratio remained 11.07. As far as the returns are concerned, JNJ’s return on equity was recorded as 17.81% and return on investment increased 11.19% while its return on asset stayed at 8.95%.

The stock showed weekly upbeat performance of 2.36% which was maintained for the month at 5.37%. Likewise the positive performance for the quarter was recorded as 15.92% and for the year was 34.78% while the YTD performance remained at 19.99%.

DO NOT TRADE ANY STOCK WITHOUT LEVEL 2 STOCK QUOTES! delivers it's user with the most in-depth Level 2 Quotation System available on the Planet! NO Downloads, NO Widgets, NO Plugins required! Stay on TOP of your trades with! CLICK HERE TO START YOUR FREE 30-DAY TRIAL

This entry was posted in Healthcare, Latest Headlines and tagged , , , , , , , , , , , . Bookmark the permalink.